Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial

By C. Creutzberg, W. V. van Putten, P. Koper, M. Lybeert, J. Jobsen, C. Wárlám-Rodenhuis, Karin A J de Winter, L. Lutgens, Ae J C J M Van Den Bergh, E. de Steen-Banasik and 1 more. 2001

704 citations recorded by the source corpus.

Subfields: Epidemiology, Obstetrics and Gynecology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/717d3aec66201163287ea68fcd2876f7b9ce014c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Obstetrics and Gynecology

In Reproductive Medicine

Citations in the corpus

Post operative radiation therapy in endometrial carcinoma : reducing overtreatment and improving quality of life (2013, background): “20 Both PORTEC-1 and GOG#99 trials established risk factors to better select patients at risk of recurrence within the intermediate risk group.(50,51) Using these risk factors (age, grade, depth of myometrial invasion and lymph vascular space invasion), in both trials devised a so-called high-interm”
A clinically applicable molecular-based classification for endometrial cancers (2015, methodology): “…based on post-surgical staging pathologic examination (principally histotype, tumour grade and stage) that may help guide treatment(s) (Creutzberg et al, 2000; Fanning, 2001; Keys et al, 2004; Mariani et al, 2008; Kwon et al, 2009; Colombo et al, 2013; AlHilli et al, 2014; Bendifallah…”
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts (2016, background): “The design and clinical results of both randomized trials havebeenpublishedpreviously (4, 7).”
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer (2015, methodology): “In this subgroup, the 5-year risk of locoregional recurrence was 20% for observation versus 5% for adjuvant RT, and only in this subgroup was the risk of relapse deemed high enough to consider adjuvant RT.(117) In the GOG99 trial, the definition of risk groups was based on risk factors for overall r”
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. (2015, background): “In this subgroup, the 5-year risk of locoregional recurrencewas 20% for observation versus 5% for adjuvant RT, and only in this subgroup was the risk of relapse deemed high enough to consider adjuvant RT [117].”